Please login to the form below

Not currently logged in
Email:
Password:

sickle cell disease

This page shows the latest sickle cell disease news and features for those working in and with pharma, biotech and healthcare.

Allergan builds on gene editing deal

Allergan builds on gene editing deal

ocular disease, including EDIT-101. ... Back in March, the US regulator halted Vertex Pharma’s planned trial involving CRISPR for sickle cell disease, which will likely delay the use of CRISPR-based therapies in humans.

Latest news

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    While previous read-outs had prepared the ground for this remarkable result, a similar success in sickle cell disease also unveiled at EHA came as a very welcome surprise for the ... sickle cell disease.

  • Pharma deals continue to slide Pharma deals continue to slide

    Gevokizumab plus IP for use of IL-1 beta targeting antibodies for cardiovascular disease. ... 425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell therapy for sickle cell disease.

  • Deal Watch November 2016 Deal Watch November 2016

    antibody, SelG1, after the completion of a phase II study in patients with sickle cell disease (SCD). ... lead product - SelG1, anti-P-selection mAb for reduction of vaso-occlusive pain crises in patients with sickle cell.

  • Deal Watch October 2015 Deal Watch October 2015

    The collaboration between CRISPR Therapeutics and Vertex will evaluate the use of CRISPR/Cas9 in a number of diseases with defined genetic targets, including cystic fibrosis and sickle cell disease. ... 17, 200. CRISPR Therapeutics/ Vertex Pharmaceuticals

  • Pharma deals during August 2014 Pharma deals during August 2014

    It also has potential utility in treating systemic sclerosis-related Interstitial Lung Disease. ... It is currently being investigated as the sole stem cell source in a phase I/II study to treat haematological malignancies such as leukaemia and lymphoma

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Cellerant appoints William Reed as VP clinical development Cellerant appoints William Reed as VP clinical development

    He has previous experience in treatments for blood conditions, spending time as director, clinical research and medical affairs at Cerus, where he worked on a programme for sickle cell disease. ... transplantation, leukaemia and acute radiation syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics